
    
      60 type II diabetic men with erectile dysfunction will be enrolled in this trial, evaluated
      over a 12 week period. Randomization into one of two arms (placebo, daily sildenafil 50mg)
      will be a doubly blinded. Subjects will be followed by IIEF, diaries and brachial forearm
      medial dilatation duplex scans, urinary microalbuminuria and serum chemistry.

      Study time-points are at baseline, 6 and 12 weeks.

      Study participants will be instructed to use the study medication at the specified frequency
      but will be allowed flexibility to suit their erectile needs.
    
  